The AIM2 expression is highly reduced in melanoma, colorectal cancer, and prostate cancer, whereas it is upregulated in hepatocellular carcinoma, nasopharyngeal cancer, and oral squamous cell carcinoma. This evidence concerns the gene AIM2 and prostate cancer.